Message from the Editor-in-Chief

*Immuno* provides an advanced forum for studies on all aspects of immunological science and medicine. Our fields of interest include basic and clinical research on the developing fields of immunology, such as immunogenomics, immunoproteomics, immunometabolomics, and immunomicrobiomics, which should contribute to improving the understanding of the yet-unknown aspects of the human immune system, as well as the development of innovative immunotherapy and vaccines through translational research. In addition, we are planning a series of Special Issues focusing on immunology topics of particular interest and importance. We hope that the advantages of open access, high-quality standards, and rapid publication will encourage scientists and practitioners to choose *Immuno* to disseminate their research and opinion. We are looking forward to receiving your submissions to *Immuno*.

Author Benefits

- **Open Access** Unlimited and free access for readers
- **No Copyright Constraints** Retain copyright of your work and free use of your article
- **Thorough Peer-Review**
- **Discounts on Article Processing Charges (APC)** If you belong to an institute that participates with the MDPI Institutional Open Access Program
- **Rapid Publication** First decision provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2022)
**Aims and Scope**

*Immuno* (ISSN 2673-5601) is an international, peer-reviewed, scientific open access journal that provides an advanced forum for studies related to basic and clinical immunology research. The journal publishes reviews, regular research papers, conference reports and communications in quarterly issues. Our aim is to publish papers that are of significant impact to the immunology community.

This journal covers all aspects of immunological science and medicine from basic research to clinical research. Translational research is most welcome. Fields of interest include, but are not limited to, the following:

- Innate immunity and inflammation;
- Acquired immunity;
- Synthetic immunity and immunoengineering;
- Structural immunology;
- Immunogenetics, immunogenomics, immunoproteomics and immunometabolomics;
- Infectious immunology and vaccines;
- Cancer immunology and immunotherapy;
- Autoimmunity and immunoregulation;
- Developmental immunology and immunodeficiency;
- Reproductive immunology;
- Transplantation immunology;
- Immunodermatology;
- Mucosal immunology;
- Neuroimmunology;
- Immunopathology and immunohistology;
- Clinical/translational immunology.

**Editorial Office**

*Immuno* Editorial Office
immuno@mdpi.com
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
www.mdpi.com
mdpi.com/journal/immuno